Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.
P/E ratio for Enanta Pharmaceuticals, Inc. (ENTA)
P/E ratio as of 2024: -1.89
According to Enanta Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.89. At the end of 2023 the company had a P/E ratio of -1.75.
P/E ratio history for Enanta Pharmaceuticals, Inc. from 2010 to 2024
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2024 | -1.89 |
| 2023 | -1.75 |
| 2022 | -8.78 |
| 2021 | -14.51 |
| 2020 | -25.24 |
| 2019 | 25.37 |
| 2018 | 24.14 |
| 2017 | 50.38 |
| 2016 | 23.25 |
| 2015 | 8.54 |
| 2014 | 21.09 |
| 2013 | 23.30 |
| 2012 | 0.93 |
| 2011 | 0.85 |
| 2010 | 27.70 |